Clinical trials: HIV-infection/AIDS
HIV-1 Infections
Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
Raltegravir not only has a unique mechanism of action, but may also have other unique effects on suppression of viral replication, viral reservoir, and immune reconstitution in blood and other important compartments.
- Trial name
- ICE-002 (NCT00984152)
- Testing
- TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily, TDF/FTC + Efavirenz (Atripla) Once-Daily
- Where
- 5 sites in United States
- Sponsor
- Rush University Medical Center
Candidiasis, Mycoses
Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy
The primary purpose of this protocol is to provide fluconazole for the treatment of individual patients who require therapy for serious or life-threatening systemic fungal infection, who have failed on conventional antifungal…
- Conditions
- Candidiasis, Mycoses, HIV Infections
- Trial name
- NCT00002038
- Testing
- Fluconazole
- Where
- United States
- Sponsor
- Pfizer
Latent Tuberculosis Infection
Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV
Tuberculosis (TB) is the prototypical disease of poverty as it disproportionately affects marginalized and impoverished communities.
- Trial name
- 3HP-LTBI (NCT03702049)
- Testing
- Nurse-led Community Health Worker TBI (RN/CHW TBI) program
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of California, Irvine
Telemedicine, HIV-1-infection
Telemedicine in HIV Care in Buenos Aires
The aim of this investigation is to conduct an implementation research to facilitate and evaluate the implementation of VCT((Videoconsult through telemedicine) among HIV HCP(healthcare providers) and PLWH(people living with HIV)
- Trial name
- NCT04513496
- Volunteers
- 4,000 people
- Sponsor
- Fundacion Ibis
HIV Infections
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
The clinical schedule will consist of 3 injections of CD40.HIVRI.Env (VRIPRO) at weeks 0, 4, and 24.40 volunteers without HIV and in overall good health, aged 18 to 60 years, who previously participated in the HVTN 706 trial.
- Trial name
- NCT06665646
- Testing
- CD40.HIVRI.Env (VRIPRO), Hiltonol Poly-ICLC-adjuvant
- Where
- 9 sites in United States, Peru
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Pulmonary, HIV
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis
The PRESCIENT trial is a Phase IIc, open-label, randomized trial that compared a 12-week regimen of bedaquiline (BDQ), clofazimine (CFZ), pyrazinamide (PZA), and delamanid (DLM) with standard treatment for drug-susceptible…
- Trial name
- PRESCIENT (NCT05556746)
- Testing
- Bedaquiline (BDQ), Clofazimine (CFZ), Pyrazinamide (PZA)
- Where
- 2 sites in Haiti, South Africa
- Volunteers
- 94 people
- Sponsor
- Brigham and Women's Hospital
Prevention of HIV Infection, HIV Antibodies
Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults
Background: Antibodies help the body fight infection. VRC01LS is an antibody directed against HIV virus. HIV attacks the immune system. In animals, VRC01LS inactivated many types of HIV viruses.
- Conditions
- Prevention of HIV Infection, HIV Antibodies, Monoclonal Antibody, Human, Neutralizing Antibody
- Trial name
- NCT02599896
- Testing
- VRC-HIVMAB080-00-AB (VRC01LS), VRC-HIVMAB060-00-AB (VRC01)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Tuberculosis
TasP in Correctional Facilities
At correctional facilities in Zambia and South Africa, a cross-sectional study design will be used to characterize the full continuum of integrated HIV/TB care under Treatment as Prevention (TasP), and will enrich this approach…
- Trial name
- NCT02946762
- Testing
- Test and treat
- Where
- Zambia
- Volunteers
- 419 people
- Sponsor
- University of North Carolina, Chapel Hill
AIDS-related Dementia Complex
Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals
The purpose of this study is to assess whether a boosting by cobicistat results in similar concentrations of darunavir in the brain compared to a boosting by ritonavir.
- Trial name
- NCT02503462
- Testing
- Darunavir, ritonavir, cobicistat
- Where
- Switzerland
- Volunteers
- 7 people
- Sponsor
- University Hospital, Basel, Switzerland
HIV Infection, Alcohol Consumption
Boston ARCH 4F Intervention to Reduce Fall Risk in People With HIV and Alcohol Use
This study is being conducted to assess the acceptability and feasibility of a randomized trial of a 10 week virtual intervention to reduce fall risk in people with HIV who consume alcohol.
- Conditions
- HIV Infection, Alcohol Consumption, Falls, Accidental, Falls
- Trial name
- NCT04804579
- Testing
- Fall Prevention Intervention
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Boston University
Acquired Immunodeficiency Syndrome
Pharmacokinetic Study of Interaction Between Nevirapine and Methadone in HIV-1 Infected, Opioid-dependent Adults
The purpose of this study was to determine the effects of nevirapine treatment on the pharmacokinetics of methadone in HIV-1 infected, opioid-dependent adults who had been on a stable methadone maintenance therapy for at least…
- Trial name
- NCT00273988
- Testing
- nevirapine
- Where
- Ireland
- Volunteers
- 10 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
TMC114-C201: A Study to Determine the Antiviral Activity of TMC114 in Patients With Multiple Protease Inhibitor (PI) Resistant Human Immunodeficiency Virus (HIV) Strains
The purpose of this study is to determine the antiviral activity, safety and tolerability of 14 days of different doses of TMC114 to treat HIV-1 positive patients whose condition is failing on a current treatment regimen that…
- Trial name
- NCT00964327
- Testing
- TMC114
- Volunteers
- 42 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV-1-infection
ANRS 12406 EvvA Study
ANRS 12406 EvvA is an observational, longitudinal and monocentric study evaluating the virological success rate in HIV-infected adolescents on antiretroviral therapy in Cameroon.
- Trial name
- EvvA (NCT04593979)
- Where
- Cameroon
- Volunteers
- 289 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC
To evaluate the pharmacokinetics of Retrovir (AZT) administered orally as 1 of 3 doses in the treatment of patients with severe clinical and laboratory manifestations of HIV infection.
- Trial name
- NCT00002046
- Testing
- Zidovudine
- Where
- 11 sites in United States
- Sponsor
- Glaxo Wellcome
HIV Infections
Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study
Multicenter, randomized, open label pilot clinical trial with two parallel arms aimed to compare the efficacy of Raltegravir (RAL) 1200mg QD vs Darunavir/Cobicistat (DRV-cb) 800-150mg QD both in combination with…
- Trial name
- ROTDIP (NCT03842488)
- Testing
- Experimental: RAL QD, Active comparator: DRV/cb
- Volunteers
- 75 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Pneumonia, Pneumocystis Carinii, HIV Infections
A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia
To evaluate and compare 3 anti-pneumocystis regimens plus zidovudine (AZT) in persons with advanced HIV disease and T4 cell count < 200 cells/mm3.
- Trial name
- NCT00001003
- Testing
- Pentamidine isethionate, Zidovudine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
MaxART: Early Access to ART for All in Swaziland
The purpose of this study is to evaluate the feasibility, acceptability, clinical outcomes, affordability, and scalability of offering early antiretroviral treatment to all HIV-positive individuals in Swaziland's…
- Trial name
- MaxART (NCT02909218)
- Testing
- Early Access to ART for All
- Where
- Eswatini
- Volunteers
- 3,485 people, healthy volunteers welcome
- Sponsor
- Clinton Health Access Initiative Inc.
Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus
CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS
This study is being done to compare three strategies to deliver HCV treatment with ledipasvir/sofosbuvir which is an approved therapy which is administered as one tablet by mouth daily for 12 weeks.
- Trial name
- CHAMPS (NCT02402218)
- Testing
- Usual care plus peer-mentors, Usual care plus incentives, Usual Care
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Johns Hopkins University
HIV Infections
Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada
the trial assessed the pharmacokinetics and long term plasma exposure of the following antiretrovirals: atazanavir when combined to ritonavir and the tenofovir/emtricitabine fixed-dose combination.
- Trial name
- ANRS134COPHAR3 (NCT00528060)
- Testing
- Atazanavir, Ritonavir, Tenofovir/emtricitabine
- Where
- 2 sites in France
- Volunteers
- 35 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV-1 Infection
Researching Alveolar Macrophage Improvements With Supplements in HIV
HIV infection causes systemic zinc deficiency and oxidative stress that impairs host immunity in the alveolar space.The purpose of this study is to see if taking two nutritional supplements, zinc and SAMe (S-adenosylmethionine)…
- Trial name
- RAISe (NCT02264860)
- Testing
- Zinc and SAMe
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Emory University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.